Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control
EJS Sonuga-Barke, D Coghill, T Wigal… - Journal of child and …, 2009 - liebertpub.com
Abstract Background: Methylphenidate (MPH)-related adverse events are well
characterized. Their predictors and their relationship with therapeutic effects are less well …
characterized. Their predictors and their relationship with therapeutic effects are less well …
Pre-existing comorbid emotional symptoms moderate short-term methylphenidate adverse effects in a randomized trial of children with attention-deficit/hyperactivity …
TE Froehlich, WB Brinkman, JL Peugh… - Journal of Child and …, 2020 - liebertpub.com
Objective: We sought to ascertain whether baseline anxiety/depression and oppositional
defiant disorder (ODD) symptoms impacted the experience of short-term methylphenidate …
defiant disorder (ODD) symptoms impacted the experience of short-term methylphenidate …
No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy
BACKGROUND AND OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) is the
most frequent psychiatric disorder in children and adolescents and is often treated with …
most frequent psychiatric disorder in children and adolescents and is often treated with …
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case …
JY Shin, EE Roughead, BJ Park, NL Pratt - bmj, 2016 - bmj.com
Objective To determine whether treatment with methylphenidate in children and young
people with attention-deficit/hyperactivity disorder (ADHD) was associated with …
people with attention-deficit/hyperactivity disorder (ADHD) was associated with …
[HTML][HTML] Comorbidities in ADHD children treated with methylphenidate: a database study
AA Kraut, I Langner, C Lindemann, T Banaschewski… - BMC psychiatry, 2013 - Springer
Background Methylphenidate (MPH) is the most common drug treatment of attention
deficit/hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in …
deficit/hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in …
Genetic influence on efficacy of pharmacotherapy for pediatric attention-deficit/hyperactivity disorder: overview and current status of research
NA Elsayed, KM Yamamoto, TE Froehlich - CNS drugs, 2020 - Springer
Multiple stimulant and non-stimulant medications are approved for the treatment of attention-
deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood …
deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood …
Patterns and profiles of methylphenidate use both in children and adults
V Pauly, E Frauger, M Lepelley… - British journal of …, 2018 - Wiley Online Library
Aim The aim of the present study was to characterize patterns of use of methylphenidate
(MPH), a prescription stimulant medication recommended in the treatment of attention deficit …
(MPH), a prescription stimulant medication recommended in the treatment of attention deficit …
Methylphenidate: gender trends in adult and pediatric populations over a 7 year period
C Ehrhardt, Q Boucherie, V Pauly, D Braunstein… - Therapies, 2017 - Elsevier
Objective Methylphenidate (MPH) is a prescription-stimulant medication which is authorized
in France for two indications: attention-deficit hyperactivity disorder in children (aged≥ 6 …
in France for two indications: attention-deficit hyperactivity disorder in children (aged≥ 6 …
Paediatric methylphenidate (Ritalin®) restrictive conditions of prescription in France
C Frances, G Hoizey, H Millart… - British journal of clinical …, 2004 - ncbi.nlm.nih.gov
Methylphenidate (Ritalin®, Novartis Pharma, 92500 Rueil Malmaison Cedex, France) is the
only psychostimulant approved in France, since July 1995, for the treatment of attention …
only psychostimulant approved in France, since July 1995, for the treatment of attention …
Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants
YK Lyauk, C Stage, TK Bergmann… - Clinical and …, 2016 - Wiley Online Library
The aim of this study was to identify demographic and genetic factors that significantly affect
methylphenidate (MPH) pharmacokinetics (PK), and may help explain interindividual …
methylphenidate (MPH) pharmacokinetics (PK), and may help explain interindividual …